Matica Bio and VaxDome Partner to Develop Antigen-Agnostic Antiviral-Vaccine Hybrids with Influenza as One of the Disease Models
· cision pr newswire
AI Briefing
- Matica Bio partners with VaxDome to develop antiviral-vaccine hybrids targeting influenza and other diseases.
- Antigen-agnostic technology aims to boost immune response against multiple viral strains.
- Collaboration aims to create novel antiviral-vaccine solutions for various diseases.
Source Summary
COLLEGE STATION, Texas, July 6, 2026 /PRNewswire/ -- Matica Biotechnology, Inc. ("Matica Bio"), a viral vector contract development and manufacturing organization (CDMO), is partnering with Texas-based biotech VaxDome Inc. to bring its novel antigen-agnostic antiviral-vaccine hybrid...
Advertisement